SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.17847452 USD and is down -3.32 over the last 24 hours. It is currently trading on 1894 active market(s) with $2,362,443,159.56 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs sharp underperformance and choppy decline are driving discussion, with traders debating broader crypto weakness and midterm-related uncertainty over the Clarity Act and regulatory outlook. Bearish frustration over stagnant performance, Ripples token sales and perceived utility is countered by dip-buyers and long-term holders.

Redwire Corp. engages in the development and provision of space and defense technologies and mission-critical solutions for government, commercial, and civil customers. Its offerings include spacecraft platforms, space infrastructure, avionics, sensors and payloads, power generation systems, radio frequency systems, microgravity research and manufacturing technologies, autonomous systems, optical sensors, and digital engineering solutions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwires quarterly results are driving attention: revenue came in below expectations, while gross margins and backlog reached records and full-year guidance was reaffirmed. Bulls view the shortfall as a timing issue and point to improving operations; skeptics question whether the company can convert its backlog into revenue and reach profitability.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axons sharp selloff follows a Q3 earnings miss and a lower full-year outlook, with federal Dedrone deployments delayed and expected to shift out of 2026. Traders are debating whether the drop is an overreaction to contract timing or a valuation reset, while also raising concerns about margins and stock-based compensation; some are buying the dip as others expect further downside.

Charter Communications, Inc. engages in providing broadband communications services. Its services include Spectrum TV, Spectrum Internet, and Spectrum Voice. It offers business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Its advertising sales division, Spectrum Reach, offers local, regional, and national businesses the opportunity to advertise in individual and multiple service areas on cable television networks and advanced advertising platforms. The company was founded in 1993 and is headquartered in Stamford, CT.

Charter Communications Inc. - Ordinary Shares - Class A

Charters third-quarter results are drawing attention, particularly worsening broadband subscriber losses and a large franchise impairment that contributed to a reported loss. Bearish traders see continued customer erosion, debt and the Cox integration as risks, while bulls point to anticipated cost savings, mobile growth and cash flow as potential offsets.

Corteva, Inc. is a global pure-play agriculture company that combines innovative technologies, high-touch customer engagement and operational execution to profitably deliver solutions for the world's most pressing agriculture challenges. It generates advantaged market preference through its unique distribution strategy, together with its balanced and globally diverse mix of seed, crop protection, and digital products and services. The company leverages recognized agricultural brands and a robust technology pipeline to maximize productivity for farmers while working with stakeholders throughout the food system to fulfill its promise of enriching the lives of those who produce and those who consume, ensuring progress for generations to come. Corteva was founded in 1802 and is headquartered in Indianapolis, IN.

Corteva Inc

Cortevas seed-business spin-off into Vylor and its accompanying index transition are driving discussion, as traders debate whether post-spin selling and rebalancing explain the sharp repricing. Some see the standalone crop-protection business and analyst upgrades as reasons for optimism, while others remain concerned about litigation, the business outlook, and continued selling.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A strong quarterly earnings beat and raised revenue outlook, powered by demand for Mounjaro and Zepbound, have driven attention to Lillys rally and record highs. Bulls point to continued GLP-1 growth and pipeline prospects, while skeptics flag the premium valuation, pricing pressure, and weaker-than-expected Foundayo uptake.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyxs quarterly results and restructuring are driving attention: the company reported a modest earnings and revenue miss, announced a roughly 20% workforce reduction and deeper R&D cuts, and reaffirmed its 2027 profitability goal. Traders are split between viewing the cost reductions and new therapy launches as progress and worrying about the miss, pipeline setbacks, and weak share-price reaction.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports priced stock and convertible-note offering is driving the discussion, with traders debating the dilution and why the company is raising capital despite its cash runway. Some bulls point to recent insider buying and positive Phase 2 results for RAP-219, while others worry the financing could weigh on shares.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs strong quarterly results, raised full-year revenue outlook, and expanding backlog are driving a sharp rebound in the shares. Traders are encouraged by growth and commercial momentum, while others question revenue quality, cash burn, dilution, and whether the rally can last.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Fireflys large engine, technology-licensing and engineering-support agreement with AST SpaceMobile for its planned heavy-lift rocket is driving attention. Traders largely view the partnership as validation of Fireflys propulsion business and a boost to its backlog, while some question the deals funding and share components and whether either company can execute its rocket plans.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

UiPath Named a Leader in Everest Group's 2026 Agentic Process Automation Platform and Full Suite APAP PEAK Matrix Assessments

UiPath, Inc. (NYSE: PATH), a leader in business orchestration and automation, today announced it has been named a Leader and Star Performer in the Everest Group Agentic Process Automation Platform (APAP) and Full Suite APAP PEAK Matrix Assessment 2026. In an evaluation of 29 APAP providers and 15...

UiPath Announces Third Quarter Fiscal 2027 Financial Results Conference Call

UiPath, Inc. (NYSE: PATH), a leader in business orchestration and automation, today announced it will report financial results for its third quarter fiscal 2027 ended October 31, 2026 after the market closes on Thursday, December 3, 2026. Management will host a conference call and webcast to...

Is Most-Watched Stock UiPath, Inc. (PATH) Worth Betting on Now?

UiPath (PATH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

UiPath vs. SentinelOne: Which Technology Stock Is a Better Buy for 2027?

Key PointsUiPath has successfully transitioned to profitability while expanding its orchestration platform for AI agents and robots...

UiPath (PATH) Falls More Steeply Than Broader Market: What Investors Need to Know

In the most recent trading session, UiPath (PATH) closed at $13.34, indicating a -2.84% shift from the previous trading day.

Can UiPath's Rising ARR Drive Sustained Growth for PATH Stock?

UiPath's ARR reaches $1.94 billion as enterprise demand for AI-driven automation grows, but competition and monetization challenges remain.

PATH or APP: Which AI-driven Tech Stock Should You Bet on?

UiPath's expanding AI automation platform, improving profitability and lower valuation strengthen its case against AppLovin's faster-growing ad business.

UiPath (PATH) Surpasses Market Returns: Some Facts Worth Knowing

UiPath (PATH) closed the most recent trading day at $14.3, moving +1.2% from the previous trading session.

UiPath, Inc. (PATH) is Attracting Investor Attention: Here is What You Should Know  

Zacks.com users have recently been watching UiPath (PATH) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

UiPath (PATH) Outpaces Stock Market Gains: What You Should Know

UiPath (PATH) reached $13.43 at the closing of the latest trading day, reflecting a +2.36% change compared to its last close.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

PATH Stock Wrapped Its Worst Week In 4 Months: UiPath Wins Higher Price Targets, But Analysts Still Want AI Proof 

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Bank of America raised its UiPath price target to $15 but kept an Underperform rating, while Truist lifted its target to $17 and maintained Hold.&nbsp;</li><li>Bank of America said UiPath’s AI opportunity remains unproven for boosting ARR growth.</li><li>TD Cowen also lifted its price target to $16, citing steady execution and growing AI adoption.</li></ul><p>&nbsp;UiPath Inc. (PATH) has garnered higher price targets from several Wall Street analysts after its fiscal second-quarter results, but enthusiasm remains tempered by questions over artificial intelligence’s impact on growth. Analysts cited solid ARR trends and rising AI adoption while waiting for clearer evidence that the technology can boost the company’s revenue.&nbsp;</p><p><a href="https://stocktwits.com/symbol/PATH">UiPath stock</a> edged 0.2% higher in Tuesday’s premarket after plunging 16% last week, its worst in over four months.</p><h2 class="st-heading-2">BofA, Truist Raise UiPath&nbsp;Price Target, But Await Faster AI Growth&nbsp;</h2><p>On Sunday, Bank of America analyst Koji Ikeda increased his price target on PATH to $15 from $13 while maintaining an ‘Underperform’ rating. Ikeda said the second-quarter (Q2) earnings did little to settle the central question surrounding UiPath: whether AI will materially speed up annual recurring revenue growth. Still, BofA adjusted its financial model to account for stronger margin expectations.</p><p>Truist raised its price target to $17 from $12 but kept a Hold rating. The firm sees more agentic AI deals and some improvement in customer growth, but wants to see faster growth before becoming more positive.&nbsp;</p><h2 class="st-heading-2">TD Cowen Highlights UiPath’s Steady Execution And AI Adoption&nbsp;</h2><p>DA Davidson analyst Lucky Schreiner raised the price target to $16 from $12 and retained a ‘Neutral’ rating. Schreiner viewed Q2 favorably, noting that UiPath exceeded expectations for annual recurring revenue (ARR) and modestly increased its fiscal 2027 ARR outlook. The upcoming investor day on Sept. 22 could give investors more detail on how management plans to push growth higher.</p><p>TD Cowen raised its price target to $16 from $13 but kept a Hold rating. The firm said Q2 performance was steady, ARR remained strong, customer retention was stable, and AI use continued to grow.&nbsp;</p><p>UiPath’s Q2 revenue&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-path-stock-tumbling-over-7-in-overnight-trading/cZswooYRJwG">increased</a> 13% to $410.26 million, above analysts’ estimate of $397.8 million, as per Fiscal Ai data. Adjusted earnings came in at $0.15 per share, matching expectations. However, Q2 gross margin fell to 80% from 82% last year.&nbsp;</p><h2 class="st-heading-2">What PATH Retail Traders Are Saying</h2><p>On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory.&nbsp;</p><p>A user&nbsp;<a href="https://stocktwits.com/Peterinvestt/message/663734948">said</a>, “Path is still relatively cheap, trading at a forward price-to-sales ratio of 4.4 times for a high gross margin, recurring business model.”</p><p>Another user&nbsp;<a href="https://stocktwits.com/Carl2233/message/663747373">said</a>, “They need to step up and start buying back more stock more aggressively. IMO I am long.”&nbsp;</p><p>PATH stock has tumbled over 7% year-to-date.&nbsp;</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/baba-stock-slips-overnight-alibaba-s-ai-spending-draws-investor-scrutiny-analysts-split/cZt3ny1RJUb">BABA Stock Slips Overnight: Alibaba’s AI Spending Draws Investor Scrutiny, Analysts Split</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

The UiPath logo appears on a smartphone screen and on a laptop computer screen in this photo illustration in Athens, Greece, on October 3, 2025. (Photo Illustration by Nikolas Kokovlis/NurPhoto via Getty Images)

Wall Street remains cautious about whether AI can drive faster growth and stronger revenue for UiPath.

PATH Stock Wrapped Its Worst Week In 4 Months: UiPath Wins Higher Price Targets, But Analysts Still Want AI Proof

Wall Street remains cautious about whether AI can drive faster growth and stronger revenue for UiPath. 


Global X Funds Global X Robotics & Artificial Intelligence ETF

UiPath Inc

$DELL

$HOOD

$ASTS

$PATH

Which of these trending stocks are you most bullish on for the next 5 years?

Feed

News

Sentiment

Earnings

Fundamentals

Info

PATH News